Antibe Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Antibe Therapeutics şirketinin toplam hissedar öz sermayesi CA$25.9M ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$56.4M ve CA$30.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$24.91m
Eşitlik	CA$25.94m
Toplam yükümlülükler	CA$30.43m
Toplam varlıklar	CA$56.36m

Son finansal sağlık güncellemeleri

Recent updates

Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

Dec 15

We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Mar 20

Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

Oct 16

Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

Feb 11

We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Jan 07

Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)

Jul 31

Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021

Jul 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ATE 'nin kısa vadeli varlıkları ( CA$28.1M ) kısa vadeli yükümlülüklerini ( CA$2.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: ATE şirketinin kısa vadeli varlıkları ( CA$28.1M ) uzun vadeli yükümlülüklerini ( CA$27.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ATE borçsuzdur.

Borcun Azaltılması: ATE şirketinin 5 yıl önce borç/öz sermaye oranı 35.8% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ATE şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ATE serbest nakit akışı her yıl % 14.9 1.3 yıl yetecek nakit akışına sahip olacaktır.

Antibe Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics Inc. Auditor Raises 'Going Concern' Doubt

Recent updates

Antibe Therapeutics Inc. Announces Board Resignations

Antibe Therapeutics Inc. Announces Board Resignations

New major risk - Market cap size

Nuance Pharma Limited Commences Legal Action Against Antibe Therapeutics Inc. in the Ontario Superior Court Legal Action

Price target decreased by 14% to CA$1.50

New minor risk - Profitability

Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

Insufficient new directors

Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation

New minor risk - Share price stability

Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation

Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of Otenaproxesul

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Profitability

Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023

Forecast to breakeven in 2026

Price target increased by 12% to CA$2.35

We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Antibe Therapeutics Inc. Announces Retirement of Dr. John L. Wallace from the Board of Directors

Price target increased to CA$2.35

Founder & Vice Chair recently sold CA$122k worth of stock

Price target decreased to CA$2.09

HANSAmed Limited completed the acquisition of Citagenix Inc from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million.

Antibe Therapeutics Inc. Provides Development Update for Otenaproxesul

Price target decreased to CA$2.09

First quarter 2023 earnings released: CA$0.11 loss per share (vs CA$0.13 loss in 1Q 2022)

Founder & Vice Chair recently sold CA$88k worth of stock

Price target decreased to CA$2.93

Antibe Therapeutics Inc., Annual General Meeting, Sep 09, 2022

Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs

HANSAmed Limited entered into an agreement to acquire Citagenix Inc. from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million

Consensus revenue estimates increase by 112%

Price target decreased to CA$2.53

Consensus revenue estimates increase to CA$1.81m

Consensus forecasts updated

Second quarter 2022 earnings released: CA$0.16 loss per share (vs CA$0.21 loss in 2Q 2021)

President recently bought CA$100k worth of stock

Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

First quarter 2022 earnings released: CA$0.13 loss per share (vs CA$0.16 loss in 1Q 2021)

Consensus forecasts updated

Price target decreased to CA$10.20

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings released: CA$0.66 loss per share (vs CA$0.71 loss in FY 2020)

Price target decreased to CA$15.09

Independent Chair of the Board recently sold CA$400k worth of stock

Antibe Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 35.1 million.

Price target raised to CA$16.96

Third quarter 2021 earnings released: CA$0.15 loss per share (vs CA$0.15 loss in 3Q 2020)

Revenue and earnings beat expectations

Analysts update estimates

Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China

New 90-day high: CA$5.76

Antibe Therapeutics Inc. Appoints Don Haut to Its Partnering Advisory Team

We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Analysts update estimates

Analysts update estimates

Antibe Therapeutics Inc. Announces Board Appointments

Analysts update estimates

Second quarter 2021 earnings released: CA$0.021 loss per share

Revenue and earnings beat expectations

Antibe Therapeutics Inc.(TSXV:ATE) dropped from S&P/TSX Venture Composite Index

New 90-day low: CA$0.32

Price target lowered to CA$1.86

New 90-day low: CA$0.36

Analysts lower revenue estimates to CA$8.26m